Form 8937 (12-2017)

Cat. No. 37752P

See separate instructions.

Part I Reporting Issuer

For Paperwork Reduction Act Notice, see the separate Instructions.

1	Issuer's name				2 Issuer's employer identification number (EIN)
	nthus Therapeutics Op		84-2257157		
3	Name of contact for additional information 4 Teleph			e No. of contact	5 Email address of contact
Inve	estor Relations			(929) 999-4055	ir@dianthustx.com
_		P.O. box if mail is not	delivered to s	street address) of contact	
7 Ti	mes Square, 43rd Floo	r			New York, NY 10036
8	Date of action		9 Class	ification and description	
	otember 11, 2023			Stock; Stock Options;	
10	CUSIP number	11 Serial number(S)	12 Ticker symbol	13 Account number(s)
	.				
Dr	See attachment art II Organizatio	nal Action Attac	hadditional	DNTH statements if peeded	See back of form for additional quantions
14					. See back of form for additional questions.
14	the action ► See att		pplicable, the		date against which shareholders ownership is measured for
	see all	achment.			
15	Describe the quantita share or as a percenta	ecurity in the hands of a U.S. taxpayer as an adjustment per			
16	Describe the calculati valuation dates \blacktriangleright See		asis and the	data that supports the ca	lculation, such as the market values of securities and the

Form	8937 (12	017)				Page 2
Par	t II	Drganizational Action (continued)				
17	List the	applicable Internal Revenue Code section(s) and sul	psection(s) upon which the tax tr	eatment	is based ►	See attachment.
			., .			
	0					
18	Can ar	resulting loss be recognized? ► <u>See attachment.</u>				
19	Provide	any other information necessary to implement the a	djustment, such as the reportable	e tax ye	ar ► <u>See at</u>	tachment.
	Lind	r penalties of perjury, I declare that I have examined this re	sturn including accompanying sched	lules and	statements	and to the best of my knowledge and
		it is true, correct, and complete. Declaration of preparer (o				
Sigr	n	1 1 1				
Here	_	Signature I I L L L		Date 🕨	December	1, 2023
				-		
	Prin	vour name ► Edward Carr		Title 🕨	Chief Acc	ounting Officer
Paid		Print/Type preparer's name Preparer's	signature	Date		Check if PTIN
	parer					self-employed
	Only	Firm's name				Firm's EIN ►
		Firm's address 🕨				Phone no.

Send Form 8937 (including accompanying statements) to: Department of the Treasury, Internal Revenue Service, Ogden, UT 84201-0054

Dianthus Therapeutics OpCo, Inc. (F/K/A Dianthus Therapeutics, Inc.) EIN: 84-2257157 Attachment to Form 8937

Form 8937, Part I, Box 10:

CUSIP number: 252828108 (formerly 55910K108)

Form 8937, Part II, Box 14:

On September 11, 2023, a wholly-owned direct corporate subsidiary of Magenta Therapeutics, Inc. ("Magenta") merged with and into Dianthus Therapeutics OpCo, Inc. (F/K/A Dianthus Therapeutics, Inc.) ("Dianthus OpCo"), with Dianthus OpCo surviving the merger. As a result, Dianthus OpCo became a wholly-owned subsidiary of Magenta. At the effective time of the merger, Magenta issued an aggregate of approximately 11,021,300 shares of Magenta common stock to Dianthus OpCo stockholders, based on an exchange ratio of approximately 0.2181 shares of Magenta common stock for each share of Dianthus OpCo common stock, excluding shares to be canceled pursuant to the merger agreement and dissenting shares.

Form 8937, Part II, Box 15:

Assuming the transaction qualifies as a reorganization within the meaning of Section 368(a) of the Internal Revenue Code of 1986, as amended (the "Code"), a Dianthus OpCo shareholder's aggregate tax basis in the Magenta common stock received will be the same as the aggregate tax basis of the Dianthus OpCo common stock surrendered in exchange therefor.

Form 8937, Part II, Box 16:

Assuming the transaction qualifies as a reorganization within the meaning of Section 368(a) of the Code, a Dianthus OpCo shareholder's aggregate tax basis in the Magenta common stock received will be the same as the aggregate tax basis of the Dianthus OpCo stock surrendered in exchange therefor. If a shareholder acquired Dianthus OpCo stock at different times or at different prices, the shareholder's tax basis in the shares of Magenta common stock received in the merger may be determined based on each block of Dianthus OpCo stock surrendered. Such shareholders should consult their own tax advisors regarding the identification of the basis of Magenta common stock received in the merger.

Form 8937, Part II, Box 17:

Sections 354, 358, and 368(a).

Form 8937, Part II, Box 18:

Assuming the transaction qualifies as a reorganization within the meaning of Section 368(a) of the Code, no loss will be recognized for tax purposes as a result of the merger.

Form 8937, Part II, Box 19:

The transaction occurred during the calendar year ending December 31, 2023.